A biotech company developing a proprietary platform technology of small molecule drugs targeting unmet medical needs, the lead of Atelerix Life Sciences Inc is ATLX-0199, a novel respiratory stimulant to address morbidity and death arising from drug-induced respiratory depression (DIRD) and related conditions. Current approach to drug-induced respiratory side effects from opioid or sedative medications is to administer an opioid receptor antagonist such as naloxone, which can help reverse certain life-threatening conditions. These, however, carry risks and limitations, particularly as they suppress pain control, making them problematic in the surgical and critical care settings. Atelerixs solution is found within the new platform of small molecule drugs called active thiol-based compounds (ATBCs) targeted at safely preventing or reversing respiratory depression via a novel molecular pathway. Lead drug ATLX-0199 uses a novel mechanism of action to reverse DIRD while preserving vital pain relief and sedation, with first uses targeted in the perioperative and critical care hospital settings
